Evidence map›Paper›PMID 33676587›Full record

ArticleGenes and environment : the official journal of the Japanese Environmental Mutagen Society2021

Weight of evidence approach using a TK gene mutation assay with human TK6 cells for follow-up of positive results in Ames tests: a collaborative study by MMS/JEMS.

Manabu Yasui, Takayuki Fukuda, Akiko Ukai, Jiro Maniwa, Tadashi Imamura, Tsuneo Hashizume, Haruna Yamamoto, Kaori Shibuya, Kazunori Narumi, Yohei Fujiishi and 20 more

Abstract read
In one paragraph

Article in Genes and environment : the official journal of the Japanese Environmental Mutagen Society, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

30 authors.

Manabu YasuiDivision of Genetics and Mutagenesis, National Institute of Health Sciences, 3-25-26 Tono-machi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan. m-yasui@nihs.go.jp.ORCID http://orcid.org/0000-0002-5243-8675
Takayuki FukudaTokyo Laboratory, BoZo Research Center Inc., 1-3-11, Hanegi, Setagaya-ku, Tokyo, 156-0042, Japan.
Akiko UkaiDivision of Genetics and Mutagenesis, National Institute of Health Sciences, 3-25-26 Tono-machi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Jiro ManiwaAstraZeneca KK, 3-1 Ofuka-cho, Kita-ku, Osaka, 530-0011, Japan.
Tadashi ImamuraIna Research Inc., 2148-188 Nishiminowa, Ina-shi, Nagano, 399-4501, Japan.
Tsuneo HashizumeScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2, Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
Haruna YamamotoScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2, Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
Kaori ShibuyaScientific Product Assessment Center, R&D Group, Japan Tobacco Inc., 6-2, Umegaoka, Aoba-ku, Yokohama, Kanagawa, 227-8512, Japan.
Kazunori NarumiYakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650, Japan.
Yohei FujiishiYakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650, Japan.
Emiko OkadaYakult Central Institute, 5-11 Izumi, Kunitachi-shi, Tokyo, 186-8650, Japan.
Saori FujishimaChemicals Evaluation and Research Institute, Japan, 3-822, Ishii-machi, Hita-shi, Oita, 877-0061, Japan.
Mika YamamotoAstellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.
Naoko OtaniAstellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki, 305-8585, Japan.
Maki NakamuraTokyo Laboratory, BoZo Research Center Inc., 1-3-11, Hanegi, Setagaya-ku, Tokyo, 156-0042, Japan.
Ryoichi NishimuraTokyo Laboratory, BoZo Research Center Inc., 1-3-11, Hanegi, Setagaya-ku, Tokyo, 156-0042, Japan.
Maya UedaGenotoxicology Laboratory, BioSafety Research Center Inc., 582-2 Shioshinden, Iwata-shi, Shizuoka, 437-1213, Japan.
Masayuki MishimaChugai Pharmaceutical Co., Ltd, 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Kaori MatsuzakiChugai Pharmaceutical Co., Ltd, 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Akira TakeiriChugai Pharmaceutical Co., Ltd, 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Kenji TanakaChugai Pharmaceutical Co., Ltd, 1-135, Komakado, Gotemba, Shizuoka, 412-8513, Japan.
Yuki OkadaToxicology Research Department, Teijin Institute for Bio-medical Research, Teijin Pharma Limited, 4-3-2, Asahigaoka, Hino, Tokyo, 191-8512, Japan.
Munehiro NakagawaNonclinical Research Center, LSI Medience Corporation, 14-1, Sunayama, Kamisu-shi, Ibaraki, 314-0255, Japan.
Shuichi HamadaTokyo Laboratory, BoZo Research Center Inc., 1-3-11, Hanegi, Setagaya-ku, Tokyo, 156-0042, Japan.
Akihiko KajikawaNonclinical Research Center, LSI Medience Corporation, 14-1, Sunayama, Kamisu-shi, Ibaraki, 314-0255, Japan.
Hiroshi HondaR&D Safety Science Research, Kao Corporation, Haga-Gun, Tochigi, Japan.
Jun AdachiLaboratory of Proteomics for Drug Discovery, Center for Drug Design Research, National Institutes of Biomedical Innovation, Health and Nutrition, 7-6-8 Saito-Asagi, Ibarak, Osaka, 567-0085, Japan.
Kentaro MisakiSchool of Nursing, University of Shizuoka, 52-1 Yada, Suruga-ku, Shizuoka, 422-8526, Japan.
Kumiko OgawaDivision of Pathology, National Institute of Health Sciences, 3-25-26 Tono-machi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.
Masamitsu HonmaDivision of Genetics and Mutagenesis, National Institute of Health Sciences, 3-25-26 Tono-machi, Kawasaki-ku, Kawasaki, Kanagawa, 210-9501, Japan.

Funding

Ministry of Health, Labour and Welfare H30-Food-General-003
6 · The paper itself

Abstract

backgroundConflicting results between bacterial mutagenicity tests (the Ames test) and mammalian carcinogenicity tests might be due to species differences in metabolism, genome structure, and DNA repair systems. Mutagenicity assays using human cells are thought to be an advantage as follow-up studies for positive results in Ames tests. In this collaborative study, a thymidine kinase gene mutation study (TK6 assay) using human lymphoblastoid TK6 cells, established in OECD TG490, was used to examine 10 chemicals that have conflicting results in mutagenicity studies (a positive Ames test and a negative result in rodent carcinogenicity studies).

resultsTwo of 10 test substances were negative in the overall judgment (20% effective as a follow-up test). Three of these eight positive substances were negative after the short-term treatment and positive after the 24 h treatment, despite identical treatment conditions without S9. A toxicoproteomic analysis of TK6 cells treated with 4-nitroanthranilic acid was thus used to aid the interpretation of the test results. This analysis using differentially expressed proteins after the 24 h treatment indicated that in vitro specific oxidative stress is involved in false positive response in the TK6 assay.

conclusionsThe usefulness of the TK6 assay, by current methods that have not been combined with new technologies such as proteomics, was found to be limited as a follow-up test, although it still may help to reduce some false positive results (20%) in Ames tests. Thus, the combination analysis with toxicoproteomics may be useful for interpreting false positive results raised by 24 h specific reactions in the assay, resulting in the more reduction (> 20%) of false positives in Ames test.

Indexed as

Ames testFollow-upHuman lymphoblastoid TK6 cellsTK6 assayToxicoproteomicsWeight of evidence approach

Identifiers

PMID33676587
PMCPMC7937321

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.